CD274 and cancer: Thus, therapies blocking the interaction between PD-L1 (L2) and PD-1 through either anti-PD-L1 or anti-PD-1 antibodies can remove the restriction on T cells and fully activate the antitumor immune response, which already substantially improve the outcomes of cancer patients [1–3].